Picture of Celltrion logo

068270 Celltrion Share Price

0.000.00%
kr flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Momentum

Relative Strength (%)
1m+6.51%
3m+1.11%
6m+20.75%
1yr+15.05%
Volume Change (%)
10d/3m-36.78%
Price vs... (%)
52w High-21.58%
50d MA+4.11%
200d MA+13.06%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)40.86
PEG Ratio (f)2.47
EPS Growth (f)19.84%
Dividend Yield (f)0.24%
Valuation (ttm)IndustryMarket
Price to Book Value2.37
Price to Tang. Book11.04
Price to Free Cashflow219.35
Price to Sales18.49
EV to EBITDA46.39

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital3.7%
Return on Equity5.07%
Operating Margin29.7%

Financial Summary

Year End 31st DecUnit201920202021202220232024E2025ECAGR / Avg
Total RevenueKR₩m1,128,459.881,849,115.531,893,401.222,283,967.482,176,431.533,175,3633,776,40117.25%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%+24.9+67.96+19.12-9.14-2.71+6.85+43.19n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Celltrion EPS forecast chart

Profile Summary

Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
February 27th, 1991
Public Since
July 19th, 2005
No. of Shareholders
535,903
No. of Employees
1,074
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
kr flag iconKorea Exchange - KSE
Shares in Issue
212,883,960

068270 Share Price Performance

Upcoming Events for 068270

Q2 2024 Celltrion Inc Earnings Release

Similar to 068270

Picture of Gene One Life Science logo

Gene One Life Science

kr flag iconKorea Exchange - KSE

Picture of Orient Bio logo

Orient Bio

kr flag iconKorea Exchange - KSE

FAQ